Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKesson
Colorcon
Merck
Mallinckrodt

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Mometasone furoate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for mometasone furoate and what is the scope of freedom to operate?

Mometasone furoate is the generic ingredient in six branded drugs marketed by Merck Sharp Dohme, Acp Nimble, Anda Repository, Fougera Pharms, Glenmark Generics, Taro, Intersect Ent Inc, Perrigo Israel, Perrigo New York, Torrent, Amneal Pharms, and Apotex Inc, and is included in twenty-seven NDAs. There are ten patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Mometasone furoate has twenty-four patent family members in ten countries.

There are thirty drug master file entries for mometasone furoate. Nineteen suppliers are listed for this compound.

Drug Prices for mometasone furoate

See drug prices for mometasone furoate

Drug Sales Revenue Trends for mometasone furoate

See drug sales revenues for mometasone furoate

Recent Clinical Trials for mometasone furoate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lyra TherapeuticsPhase 2
National Heart, Lung, and Blood Institute (NHLBI)Phase 2
Jeffrey GlassbergPhase 2

See all mometasone furoate clinical trials

Recent Litigation for mometasone furoate

Identify potential future generic entrants

District Court Litigation
Case NameDate
Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.2015-09-08
MERCK SHARP & DOHME CORP. v. APOTEX INC.2015-04-02
Merck Sharp & Dohme Corp. v. Amneal Pharmaceuticals LLC2015-03-20

See all mometasone furoate litigation

Pharmacology for mometasone furoate
Medical Subject Heading (MeSH) Categories for mometasone furoate
Synonyms for mometasone furoate
(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
(9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
04201GDN4R
11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester
83919-23-7
9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
919M237
A840685
AB2000407
AC-941
AC1L9AZS
AK163902
AKOS015994732
AN-15438
Asmanex
Asmanex HFA
Asmanex Twisthaler
BC228151
BDBM50148733
BPBio1_000424
BRD-K60640630-001-03-7
BRD-K60640630-001-11-0
BRN 4340538
BSPBio_000384
C07817
C27H30Cl2O6
CAS-83919-23-7
CCG-220572
CHEBI:47564
CHEMBL1161
CS-2389
D00690
Danitin
DSSTox_CID_3333
DSSTox_GSID_23333
DSSTox_RID_76981
DTXSID4023333
Ecural
Elocone
Elomet
Flumeta
HMS1569D06
HMS2096D06
HMS2235I14
HMS3713D06
HY-13693
KS-00000SPL
KS-1275
LAS 41002
M2354
MLS002153879
MolPort-003-849-257
Mometasone 17-(2-furoate)
mometasone 17-furoate
mometasone furancarboxylate
Mometasone furoate (JAN/USP)
Mometasone furoate [USAN:USP:JAN]
Mometasone Furoate Impurity G
MOMETASONE FUROATE MONOHYDRATE
Mometasone furoate, >=98% (HPLC)
Mometasone furoate, European Pharmacopoeia (EP) Reference Standard
Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material
Mometasone furoate, United States Pharmacopeia (USP) Reference Standard
Monovo
Nasonex
NCGC00016950-01
NCGC00179578-01
NCGC00179578-03
NCGC00179578-04
Nosorex
NSC-746171
NSC746171
Ovixan
Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-
Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-
Prestwick_924
Prestwick0_000572
Prestwick1_000572
Prestwick2_000572
Prestwick3_000572
Q-101380
Rimelon
s1987
Sch 32088
Sch-32088
SCHEMBL4568
Sinuva
SMR001233233
SPBio_002603
SR-01000841209
SR-01000841209-2
ST24048112
TL8005500
Tox21_110705
Tox21_110705_1
UNII-04201GDN4R
WOFMFGQZHJDGCX-ZULDAHANSA-N
ZINC3938677
Paragraph IV (Patent) Challenges for MOMETASONE FUROATE
Tradename Dosage Ingredient NDA Submissiondate
NASONEX SPRAY, METERED;NASAL mometasone furoate 020762 2009-08-07
ELOCON LOTION;TOPICAL mometasone furoate 019796 2004-06-10
ELOCON CREAM;TOPICAL mometasone furoate 019625

US Patents and Regulatory Information for mometasone furoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms MOMETASONE FUROATE mometasone furoate CREAM;TOPICAL 076171-001 Apr 8, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Apotex Inc MOMETASONE FUROATE mometasone furoate SPRAY, METERED;NASAL 091161-001 Mar 22, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 RX Yes No   Start Trial   Start Trial   Start Trial
Glenmark Generics MOMETASONE FUROATE mometasone furoate CREAM;TOPICAL 078541-001 May 28, 2008 AB RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for mometasone furoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008   Start Trial   Start Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-001 Mar 30, 2005   Start Trial   Start Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-001 Mar 30, 2005   Start Trial   Start Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008   Start Trial   Start Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-001 Mar 30, 2005   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for mometasone furoate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0112669 96C0002 Belgium   Start Trial PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
0548114 SPC/GB97/064 United Kingdom   Start Trial PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Harvard Business School
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.